Compare AU

Compare CURE vs. T3MP

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Jpmorgan Climate Chg Sol Active ETF (Managed Fund) (T3MP). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

T3MP

Popularity

Low

Low

Pearlers invested

80

1

Median incremental investment

$620.00

$567.50

Median investment frequency

Monthly

Fortnightly

Median total investment

$1,318.91

$560.52

Average age group

> 35

< 26


Key Summary

CURE

T3MP

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

T3MP.AX was created on 2022-11-28 by JPMorgan. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Fund is to achieve a return through investing in equity securities of companies with exposure to the theme of climate change solutions.

Top 3 holdings

Neurocrine Biosciences Inc (2.78 %)

AbbVie Inc (2.58 %)

Alnylam Pharmaceuticals Inc (2.56 %)

Hitachi Ltd (4.83 %)

Quanta Services Inc (4.46 %)

Trane Technologies PLC Class A (4.46 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Industrials (73.25 %)

Utilities (26.75 %)

Consumer Discretionary (9.68 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

0.55 %


Key Summary

CURE

T3MP

Issuer

Global X

JPMorgan

Tracking index

S&P Biotechnology Select Industry

MSCI All Country World Index - Benchmark TR Net

Asset class

ETF

ETF

Management fee

0.45 %

0.55 %

Price

$49.09

$61.90

Size

$36.111 million

N/A

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

0.34 %

Market

ASX

ASX

First listed date

12/11/2018

08/12/2022

Purchase fee

$6.50

$6.50


Community Stats

CURE

T3MP

Popularity

Low

Low

Pearlers invested

80

1

Median incremental investment

$620.00

$567.50

Median investment frequency

Monthly

Fortnightly

Median total investment

$1,318.91

$560.52

Average age group

> 35

< 26


Pros and Cons

CURE

T3MP

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

T3MP

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home